Opinion on Thrombosis in North America

Published within

« | 1 | 2 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Sanofi/Organon: Arixtra approved despite safety warning

There should be a strong market for Arixtra, which is approximately 50% more effective than the gold standard therapy, Lovenox, at preventing venous thromboembolism in patients undergoing lower-limb orthopedic surgery. However, Arixtra will have to carry a black box warning due to safety concerns. This is likely to hit its rate of uptake.

Published By Datamonitor
12 Dec 2001
ResearchWire
ResearchWire

Deep vein thrombosis: US cases to grow 1% per year

Published By Datamonitor
09 Apr 2002
CommentWire
CommentWire

BMS: good Vanlev news just isn't enough

Despite the positive new results, Vanlev will have great difficulty gaining FDA approval for hypertension. Even if it is approved, establishing credibility with physicians will be harder still. In the current climate, concerns over side effects look almost certain to prevent Vanlev from reaching the blockbuster status BMS once expected.

Published By Datamonitor
29 May 2002
CommentWire
CommentWire

BMS/Sanofi: latest results give further push to Plavix

Although the CREDO trial failed to meet its primary endpoint, it has confirmed that Sanofi and BMS' Plavix is effective alongside aspirin in long-term angioplasty care. Plavix is now highly likely to become the standard of care - and the results of at least eight large-scale trials for new indications look set to drive its sales beyond $4 billion in 2008.

Published By Datamonitor
20 Nov 2002
CommentWire
CommentWire

AstraZeneca: promising results for first oral anticoagulant in 50 years

The test results for AstraZeneca's new anticoagulant Exanta put the drug ahead of its 50-year-old competitor warfarin. Exanta should also be able to put up a good fight against Aventis' Lovenox, which currently dominates the post-operative venous thromboembolism market. Although the drug may have a slower start than many analysts predict, Exanta looks set for strong sales.<BR />

Published By Datamonitor
10 Apr 2003
CommentWire
CommentWire

AstraZeneca: new data for Exanta

Results of the EXULT B trial were presented at the 45th Annual Meeting of the American Society of Hematology this week. The latest research on AstraZeneca's [AZN.L] ximelagatran is once again positive, and new data will help to allay concerns over liver enzyme levels. Ximelagatran remains on track for blockbuster status.

Published By Datamonitor
12 Dec 2003
CommentWire
CommentWire

GSK: antithrombotics deal in the pipeline

GlaxoSmithKline has signed an agreement with Sanofi-Synthelabo to purchase the latter's injectable antithrombotics Fraxiparine and Arixtra. However, this agreement is conditional on Sanofi-Synthelabo successfully completing its offer for Aventis. Should the deal go through, it will give GSK valuable experience in the antithrombotics sector which will enhance its own product pipeline.

Published By Datamonitor
14 Apr 2004
CommentWire
CommentWire

Bayer: the power of three

After achieving encouraging phase II results, Bayer has revealed that it intends to seek regulatory approval for BAY-597939 by the end of 2007 and has entered talks with potential development and marketing partners. However, Bayer's best laid plans for the drug candidate may not be enough to counter the challenge of Boehringer Ingelheim's rival pipeline offering.

Published By Datamonitor
11 Aug 2005
CommentWire
CommentWire

Bayer: cardiovascular concerns could run deep

Bayer looks set to face legal action following the release of study results linking the company's blood clot drug Trasylol to adverse events including heart and kidney failure. The study findings, and the potential impacts of litigation, pose a significant threat to Bayer's cardiovascular portfolio, and thus could signal trouble for the company overall.

Published By Datamonitor
03 Feb 2006
CommentWire
CommentWire

Bayer/Nuvelo: beginning a joint adventure

Bayer and Nuvelo have started patient enrollment in a second phase III clinical trial of alfimeprase in central venous catheter occlusion. The trial marks the start of Bayer's involvement in the clinical development of the novel thrombolytic agent following a much-applauded agreement with Nuvelo. However, trials in other indications may prove to be of more benefit to Bayer's shareholders.

Published By Datamonitor
01 Mar 2006

« | 1 | 2 | » »|

No help is available.